FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 19:58:01 31/05/2024 BST | ||
| 7.43 EUR | -6.31% |
|
| Current month | -35.67% | ||
| 1 month | -35.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 7.43 | -6.31% |
| 30/05/24 | 7.93 | -0.13% |
| 29/05/24 | 7.94 | +3.79% |
| 28/05/24 | 7.65 | +9.91% |
| 27/05/24 | 6.96 | -3.60% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 07:58 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MG09F1 |
| ISIN | DE000MG09F12 |
| Date issued | 14/03/2024 |
| Strike | 590.7 $ |
| Maturity | Unlimited |
| Parity | 17.36 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.95 € |
|---|---|
| Lowest since issue | 6.96 € |
| Spread | 0.03 € |
| Spread % | 0.41% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Certificates
- Certificat
